Abstract
We evaluated the clinical usefulness of single-photon emission tomography (SPET) with technetium-99m sestamibi and indium-111 pentetreotide in breast cancer staging. Fifteen patients with clinical and/or mammographic findings suggesting T1-2N0-1 breast cancer were studied. SPET images were acquired 20 min after99mTc-sestamibi injection and 4 and 24 h after111In-pentetreotide injection. Patients underwent surgery the day after the later111In-pentetreotide acquisition. Pathological examination showed 16 tumours in the 15 patients, with one bilateral carcinoma. The mean tumour diameter was 18.7 mm. Metastatic axillary involvement was found in 6/16 tumours, with a mean of five metastatic nodes per axilla. Both tracers correctly identified 15/16 primary tumours and five of the six cases of metastatic axillary node involvement. No difference between the tracers was observed in breast cancer staging.99mTc-sestamibi seems to be the better tracer in terms of physical characteristics, execution time and cost-effectiveness. Our data suggest the future possibility of using nuclear medicine imaging to avoid axillary dissection in patients with T1 breast cancer.
References
Kolscielny S, Le Mg, Tubiana M. The natural history of human breast cancer. The relationship between involvement of axillary lymph nodes and the initiation of distant metastases.Br J Cancer 1989; 59: 775–782.
Menard S, Bufalino R, Rilke F et al. Prognosis based on primary breast carcinoma instead of pathological nodal status.Br J Cancer 1994; 70: 709–712.
Chada M, Chabon AB, Friedmann P. Predictors of axillary lymph node metastases in patients with T1 breast cancer. A multivariable analysis.Cancer 1994; 73: 350–353.
Crippa F, Agresti R, Bombardieri E, et al. Preliminary results of pre-operative axillary radioimmunoscintigraphy with In-111 B72.3 in breast cancer.Int J Oncol 1995; 6: 791–795.
Krenning EP, Kwekkeboom DJ, Bakker WH, et al. Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients.Eur J Nucl Med 1993; 20: 716–731.
Chiti A, Maffioli LS, Infante M, et al. Assessment of mediastinal involvement in lung cancer with99mTc-SestaMIBI SPET.J Nucl Med 1996; 37: 938–942.
Maffioli LS, Gasparini M, Chiti A, et al. Clinical role of technetium-99m sestamibi single-photon emission tomography in evaluating pretreated patients with brain tumors.Eur J Nucl Med 1996; 23: 308–311.
Khalkhali I, Mena I, Jouanne E. Prone scintimammography in patients with suspicions of carcinoma of the breast.J Am Coll Surg 1994; 178: 491–497.
Ell PJ. Keeping abreast of time.Eur J Nucl Med 1995; 22: 967–969.
Van Eijck CHJ, Krenning EP, Bootsma A, et al. Somatostatin-receptor scintigraphy in primary breast cancer.Lancet 1994; 343: 630–643.
Chiu ML, Kronauge JF, Piwnica-Worms D. Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis (2-methoxyisobutylisonitrile)-technetium(I) in cultured mouse fibroblasts.J Nucl Med 1990; 31: 1646–1653.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Chiti, A., Agresti, R., Maffioli, L.S. et al. Breast cancer staging using technetium-99m sestamibi and indium-111 pentetreotide single-photon emission tomography. Eur J Nucl Med 24, 192–196 (1997). https://doi.org/10.1007/BF02439552
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02439552